The 80% Crash That Redrew Bladder Cancer's Battle Lines

Johnson & Johnson's Inlexzo (approved in September 2025) posted a complete response rate of approximately 82% in trials, while CG Oncology's cretostimogene showed a 75.5% overall complete response rate. That's not a small gap; it's the difference between a drug doctors will prescribe enthusiastically and one they'll reach for only when alternatives aren't available.

Worse, durability fell off a cliff. By 12 months, enGene's response rate dropped to just 25% (Kaplan-Meier estimate). The drug was clearing tumors initially but couldn't keep them gone. Think of it like a paint job that looks great for six months, then starts peeling. Homeowners are going to pick the brand that lasts.

There was another worrying signal buried in the data: patients enrolled later in the trial (after October 2025) showed even weaker results, with only 39% achieving any complete response and just 32% at six months. The company said it's investigating why, but Wall Street didn't wait for answers.

Wall Street's Verdict Was Brutal

The analyst downgrades came in waves. Six major firms cut their ratings in a matter of hours:

• Wells Fargo went from Overweight to Equal-Weight, target from $25 to $2
• Oppenheimer dropped from Outperform, removing its $30 target entirely
• Morgan Stanley shifted to Equal-Weight
• Piper Sandler moved to Neutral with a $4 target

Leerink Partners delivered perhaps the most devastating assessment, slashing its peak sales estimate from $1 billion to just $350 million. Their projected market penetration in community settings (where most patients get treated) fell from 60% to 15%. The firm's reasoning was blunt: the data "forecloses the possibility of closing the efficacy gap" with competitors.

Only HC Wainwright maintained a Buy rating, though even they cut their target from $25 to $6. Guggenheim downgraded enGene from Buy to Neutral, joining the broader wave of skepticism.

Why Being "Approvable" Isn't Enough

This situation illustrates a harsh reality of biotech commercialization. Getting FDA approval and building a successful business are two very different things.

Leerink still gives detalimogene a 60% probability of approval (down from 70%). The safety profile is genuinely clean: mostly mild side effects, only 2.4% of patients discontinued treatment. And the low 3.2% progression rate to muscle-invasive disease is reassuring. For a smaller subset of patients, this drug might still find a role.

But "approvable" doesn't mean "commercially viable" when you're competing against established therapies with better efficacy data. enGene's pitch had always included a convenience angle: as a non-viral therapy, detalimogene could potentially be administered in community urology offices rather than specialized centers. That's a real advantage for patients and doctors. The question now is whether convenience alone can overcome a significant efficacy gap at six months.

The Bigger Picture

The NMIBC space has transformed rapidly. Just a few years ago, BCG-unresponsive patients had almost nowhere to turn. Now there are multiple approved therapies (Adstiladrin, Inlexzo, Anktiva) and a robust pipeline of candidates in development. Multiple companies are fighting for this market.

For enGene, the math has changed dramatically. The company still has significant cash reserves and plans to present fuller data at the American Urological Association meeting on May 15. A securities investigation by Johnson Fistel adds another layer of pressure, probing whether the company's earlier data presentations were misleading.

The stock now trades at approximately $1.72, which could signal either a buying opportunity for the brave or a market that's correctly pricing in diminished prospects.

One thing is clear: in oncology, "pretty good" doesn't cut it when your competitors are delivering "great." enGene built a plane while the others built jets. The question isn't whether it can fly; it's whether anyone will buy a ticket.

Your Liver Might Be the Secret Weapon Against Alzheimer's

Researchers delivered a protective gene to mouse livers and watched amyloid plaques shrink in their brains. No blood-brain barrier crossing required. This peripheral approach could rewrite the Alzheimer's treatment playbook.